The decisions made at the Greater Manchester Medicines Management Group (GMMMG) February 2025 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in February 2025 and NICE Technology appraisals published in October 2024.
Updates to formulary and RAG list
- Latanoprost / netarsudil eye drops – GREEN (following specialist advice)
- Apomorphine – APO-go 50mg/10ml syringes removed from formulary (discontinued) and replaced with 5mg/ml, 20ml cartridge (APO-go POD)
- Kay-Cee-L removed from formulary (discontinued)
- Varenicline for smoking cessation – GREEN, first choice alongside NRT and cytisinicline.
- NovoRapid Flextouch pens removed from formulary – discontinued. NovoRapid FlexPen and Penfill presentations remain on formulary and available.
- Danicopan for paroxysmal nocturnal haemoglobinuria – RED
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
- High dose opioids – communication for primary care – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- GM tariff-excluded high cost drug list – https://gmmmg.nhs.uk/guidance/high-cost-drugs/tariff-excluded-drugs-and-devices/
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.